```markdown | Earnings Briefing | Pets at Home Group Plc

```markdown

Earnings Briefing | Pets at Home Group Plc

Scoring: 0 ●●●●●

# FY26 uPBT ~£92m: Retail stabilising, Vet resilient, FY27 not upgraded

Impact on forecasts: -1–3% FY26 underlying PBT, ~0% FY27

Time saved: 35 min

FY26 effectively confirmed, but a touch light vs snapshot: Group underlying PBT is expected to be c£92m, broadly in line with prior messaging but ~2–3% below the (Feb) consensus snapshot, so this reads more like tidy-up than new information.
Retail H2 repair is the main “good news,” but still far below FY25: Retail underlying PBT of c£30m implies a sharp H2 recovery from a very weak H1, yet Retail profit remains structurally smaller than last year—so investors will likely focus on sustainability and margin mechanics rather than the FY26 endpoint.
Vet continues to carry the group despite slowing sales growth: Vet Group PBT of c£83m represents another year of progress, with management reiterating average transaction values and Care Plan growth as offsets to a “cohort lull.”
Capital returns re-framed (same total, more flexible mix): Dividend is rebased to a 50% payout ratio, with the “saving” redirected to buybacks—likely aimed at keeping total distributions steady while increasing flexibility.
Disclosure is unusually light heading into results: No revenue/LFL/KPI table (Pets Club, subscriptions mix, clinical FTE) and no Insurance update; the May prelims should matter more than usual for validating the turnaround narrative.

Financials | FY26 endpoint set; H2 Retail recovery implied

Group uPBT lands in the low-90s, as guided: FY26 underlying PBT expected at c£92m (52 weeks to 26 Mar 2026), consistent with the “stabilisation phase” established since the September reset.
Small miss vs available consensus, with rounding caveat: Versus the Feb snapshot proxy (£94.4m), the implied shortfall is ~£2.4m (~2.5%), but “c.” rounding and stale consensus limit precision.
Retail improvement is real, but the base is depressed: Retail uPBT c£30m (vs £3.5m in H1) implies a step-up in H2 profitability, but still represents a large downshift vs FY25 Retail uPBT (£72.9m).
Vet remains the profit stabiliser: Vet Group PBT c£83m looks consistent with continued profit compounding even as growth normalises; management again frames the demand slowdown as cohort-driven rather than competitive/regulatory.
Cash generation looks supportive given distributions: Year-end net debt expected at c£20m after c£85m returned via dividends/buybacks, implying balance sheet flexibility remains intact.

FY26 pre-close vs consensus: what we can (and can’t) compare

Metric	Consensus	Actual	Beat/miss
Group underlying PBT (£m)	94.37¹	c.92	Miss (c.-2.5%)
Non-underlying costs / adjustments (£m)	8.33¹	c.7	Beat (c.-16%)
Net debt (£m)	n/a	c.20	n/a
Retail profit (company PBT vs cons. segment operating income) (£m)	51.12¹,2	c.30	Miss (directional)²
Vet profit (company PBT vs cons. segment operating income) (£m)	80.58¹,2	c.83	Beat (directional)²

¹ Consensus snapshot as of 1 Feb 2026; closest available proxies used (definition mismatches noted).
² Retail/Vet are not apples-to-apples: company discloses segment PBT, while the snapshot provides segment operating income.

Implied H2 profit step-up (derived from disclosed FY26 totals)

£m	H1 FY26 actual	FY26 pre-close	Implied H2 FY26³
Group underlying PBT	36.2	c.92	c.55.8
Retail underlying PBT	3.5	c.30	c.26.5
Vet Group underlying PBT	44.9	c.83	c.38.1

³ Implied H2 = FY26 pre-close expectation minus H1 FY26 actual (interim results).

Outlook | FY27 held to consensus; uncertainty reduced, not removed

FY27 message is “in line,” not an upgrade: Management says it is “comfortable with current analyst consensus” for FY27 group underlying PBT; they cite consensus of £99m (range £90–108m).
Hedging provides some near-term cost visibility: The group states c80% of energy and FX requirements are hedged at this stage, which may dampen near-term variance versus plan.
CMA overhang framed as benign for Vet strategy: The company welcomes the CMA Final Decision Report and reiterates it expects no adverse impact on Vet Group growth ambitions (helpful for narrative risk, but not quantified financially).
Retail turnaround milestones reiterated, but still qualitative: Price investments and £20m overhead savings are said to be completed; H2 retail saw volume growth and positive LFL, with Q4 improving vs Q3—yet no magnitudes are disclosed here.

Guidance / outlook snapshot

Item	Current statement	Consensus read-through
FY26 group underlying PBT	c£92m	Small downside vs Feb snapshot (~£94.4m), but close to “in line” language
FY26 Retail underlying PBT	c£30m	Confirms Retail remains the swing factor; magnitude likely disappoints vs expectations embedded in some models
FY26 Vet Group PBT	c£83m	Supports view that Vet is offsetting Retail weakness
FY27 underlying PBT	“Comfortable with consensus” (company cites £99m)	Implies ~0% near-term change to FY27; note supplied snapshot appears higher (~£103m) and may be stale/definitionally different

What people might miss | The “light” disclosure and the cash-return reset

Key operating KPIs were dropped versus earlier updates: No Pets Club members, ACV, subscription mix, clinical FTE, revenue or quantified LFL—reducing the ability to independently validate the claimed H2 inflection (especially in Retail).
Insurance is absent from the narrative despite prior prominence: Insurance losses were previously flagged as a planned drag (and broken out as a segment at interims), but the pre-close does not mention Insurance at all.
“£20m overhead savings completed” may be timing-sensitive: Prior messaging suggested a fuller run-rate benefit in FY27; “completed” here likely refers to actions taken, but the in-year vs annualised split remains unclear until prelims.
Dividend rebased to 50% payout (buybacks take the slack): Total cash returns are said to be unchanged, but the mix change increases flexibility (buybacks can be dialled up/down more easily than dividends), which may matter to how investors underwrite distributions through a Retail recovery.

Forecast agenda | Where our driver-led model differs from consensus

Our independent FY27 landing point is close to company-cited consensus: A driver-led build (using FY26 H1 + Q3 trading + pre-close profit endpoints) yields a base-case FY27 underlying PBT around £99m—broadly matching the company’s cited consensus number.
Outer-year skew depends on Retail margin, not Vet growth: In our scenarios, FY28 upside/downside is dominated by Retail profit conversion (gross margin stabilisation after price investment + operating leverage), with Vet a steadier mid-single digit grower.
Where there may be modelling edge (either direction):
- Upside risk if FY27 captures more of the £20m savings as retained profit (vs reinvestment) and H2 FY26 Retail momentum proves durable.
- Forecast pressure if Retail’s H2 recovery was helped by non-repeatable factors (mix/timing) and if Vet’s “cohort lull” persists longer than expected.
Scenario frame (group underlying PBT): FY27 bear/base/bull ~£91m / ~£99m / ~£111m, mainly reflecting different assumptions on Retail recovery pace and Insurance loss phasing toward FY28 break-even ambitions.

```

This content is provided for general information only. It is not investment research and does not constitute advice, a recommendation, or a solicitation to trade. Primer can make mistakes - please verify independently.

Driven by AI, built by analysts.